The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...

The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...

Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...

Francis Medical, developing water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced ...

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a ...

KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...

Bayer continues to form new partnerships to expand its targets for cancer treatment, recently collaborating with MOMA and ...